**Main Education and Work Experience:** **Education:** 1980.9-1986.6 Sun Yat-sen University of Medical Sciences, Bachelor's Degree 2003.9-2007.6 Sun Yat-sen University Cancer Center, Master's Degree (Oncology), Supervisor: Lin Tongyu 2009.9-2012.07 The First Affiliated Hospital, Sun Yat-sen University, Doctoral Degree (Breast Cancer), Supervisor: Wang Shenming **Work Experience:** 1986.7~2007.2 The First Affiliated Hospital of Guangdong Pharmaceutical University, Resident, Attending Physician, Associate Chief Physician 2002.11~2007.3 The First Affiliated Hospital of Guangdong Pharmaceutical University, Deputy Director, Director of Department 2007.3~Present The First Affiliated Hospital, Sun Yat-sen University, Associate Chief Physician, Chief Physician, Director of Department **Professional Affiliations:** Chinese Society of Clinical Oncology Association (CSWOG) Secretary General Guangdong Health Management Association, Cancer Prevention and Treatment Committee Executive Vice Chairman Guangdong Hospital Association, Molecular Targeted Therapy for Cancer Prevention and Management Committee Chairman Guangdong Anti-Cancer Association, Chemotherapy Committee Vice Chairman Guangzhou Anti-Cancer Association, Hepatobiliary and Pancreatic Cancer Committee Chairman Guangzhou Anti-Cancer Association, Chemotherapy Committee Vice Chairman **Publications: Major Representative Works (Six Articles)** 1) Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem-cell-like Phenotype via Dysregulation of PITX2. 2) Zhang J X, Yun M, Xu Y, et al. GNA13 as a prognostic factor and mediator of gastric cancer progression[J]. Oncotarget, 2015. 3) Chen C, Sun P, Rong J, et al. Short Course Radiation in the Treatment of Localized Rectal cancer: A Systematic Review and Meta-Analysis[J]. Scientific Reports, 2015,5:10953. 4) Yun M, Bai H, Zhang J, et al. ULK1: A Promising Biomarker in Predicting Poor Prognosis and Therapeutic Response in Human Nasopharygeal Carcinoma[J]. PLOS ONE, 2015,10(2):e117375. 5) Chen C, Sun P, Dai Q S, et al. The Glasgow Prognostic Score predicts poor survival in cisplatin-based treated patients with metastatic nasopharyngeal carcinoma[J]. PLoS One, 2014,9(11):e112581. 6) Ouyang M, Li Y, Ye S, et al. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer[J]. PLoS One, 2014,9(5):e96228. **Monographs:** (1) 《Diagnosis and Treatment of Malignant Lymphoma》--- Editorial Board Member Publisher: People's Medical Publishing House (2) 《Clinical Practice of Pancreatic Cancer: Controversies and Consensus》--- Editorial Board Member Publisher: Guangdong Science and Technology Press (3) 《Practical Diagnosis and Treatment of Gastrointestinal Malignancies》--- Editorial Board Member Publisher: Guangdong Science and Technology Press (4) 《National Oncology Manual for County-Level Hospitals》- Secretary Unit for Editor-in-Chief Publisher: People's Medical Publishing House (5) 《Molecular Targeted Diagnosis and Treatment of Tumors》 - Deputy Editor-in-Chief Publisher: People's Medical Publishing House **Other Major Work Achievements (e.g., Awards):** In clinical medical work, standardized diagnosis and treatment are carried out according to the latest advances. In the era of precision medicine, efforts are made to provide high-level treatment for every patient. Skilled in leveraging the advantages of a high-level large comprehensive hospital, multidisciplinary team (MDT) consultations are frequently organized for patients with complex and severe conditions to develop individualized diagnosis and treatment plans. The diagnosis and treatment of complex cases have reached the domestic leading level. Actively participate in MDT consultations for tumor patients in other departments of the hospital, providing optimal diagnosis and treatment measures for a large number of complex cases. As the Director of the Department of Oncology at The First Affiliated Hospital, Sun Yat-sen University, successfully led the department in applying for and being awarded the "National Key Clinical Specialty Construction Project" and the Guangdong Provincial Key Specialty. Regularly organize and host academic conferences such as the Annual Meeting of the Molecular Targeted Therapy Committee of the Guangdong Hospital Association, the Digestive Tumor Conference of the Guangzhou Anti-Cancer Association, and the First Lung, Gastrointestinal, and Tumor Summit Forum, steadily enhancing academic influence with enthusiastic responses. Regularly hold educational lectures on tumor screening and prevention, palliative care, and rehabilitation, which are highly praised by patients and their families, achieving a 100% patient satisfaction rate throughout the year. Actively participate in cadre healthcare work and national medical team free clinics and lectures, receiving high praise, and was named "Outstanding Healthcare Worker" in 2016. Actively conduct the latest clinical trial research, initiated and led a prospective Phase III multicenter randomized clinical study of cisplatin combined with docetaxel +/- cetuximab induction chemotherapy followed by concurrent chemoradiotherapy for the treatment of newly diagnosed metastatic nasopharyngeal carcinoma. Participated in a Phase IV clinical study on the safety and efficacy of Aprepitant in preventing nausea and vomiting induced by highly emetogenic chemotherapy in China. **Research Grants:** 2010 Guangdong Natural Science Foundation "Screening and Identification of Novel Serum Biomarkers for Non-Small Cell Lung Cancer" (Principal Investigator) 2013 Guangdong Science and Technology Planning Project "Preliminary Study of MiRNA-124a on EMT, Recurrence, and Metastasis of Gastric Cancer Cells" (Principal Investigator) 2014 Guangdong Science and Technology Planning Project "Detection of AQP1 Antibodies in Serum of Non-Small Cell Lung Cancer Patients and Their Relationship with Prognosis" (Principal Investigator)